-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Avadel Pharmaceuticals Plc annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from 2013 to 2023.
- Avadel Pharmaceuticals Plc Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2023 was $0.000.
- Avadel Pharmaceuticals Plc annual Deferred Income Tax Expense (Benefit) for 2023 was $160K, a 99.4% decline from 2022.
- Avadel Pharmaceuticals Plc annual Deferred Income Tax Expense (Benefit) for 2022 was $26M.
- Avadel Pharmaceuticals Plc annual Deferred Income Tax Expense (Benefit) for 2021 was -$15.9M, a 2435% decline from 2020.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)